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interest over the last years. Many agree that the advances of mod-
ern imaging tools have clearly outdated the concept of so-called 
‘primary’ intracerebral haemorrhage. Even cerebral ‘small-vessel 
disease’ may now be categorized into more specific subtypes (am-
yloid angiopathy, hypertensive arteriolopathy, genetic small-ves-
sel disease, etc.)  [2] . In an aging population, there is also increas-
ing awareness about the impact of iatrogenic intracranial haem-
orrhage due to an increasing proportion of patients on oral 
anticoagulants and other antithrombotic medication  [3] . The dy-
namics of acute haematoma growth and its impact on clinical 
outcome are increasingly better understood  [4, 5] , and specific 
treatment algorithms such as haemostatic therapy  [6, 7] and acute 
surgical intervention  [8, 9] are currently under investigation. Sec-
ondary endpoint analyses from recent clinical trials have under-
lined the beneficial effect of antihypertensive therapy below the 
threshold of currently recommended blood pressure values for 
both primary and secondary prevention of intracerebral haemor-
rhage  [10, 11] . Clearly, there is urgent need to support clinical tri-
als to define blood pressure treatment targets, the timing of the 
achievement of such targets and related pharmacological proto-
cols. On another scale, the constant technological improvement 
and widening availability of non-invasive brain imaging tools 
leaves physicians with a growing number of patients diagnosed as 
having potential sources of intracranial haemorrhage at a stage 
before any symptoms or actual bleeding have occurred. Unrup-
tured aneurysms, unruptured brain arteriovenous malforma-
tions and clinically silent cavernous malformations – to name but 
a few – frequently create the clinical dilemma of whether and how 
to treat a patient depending on the balance between the potential 
risks and benefits of intervention versus our limited understand-
ing of the natural histories of these lesions in general  [12] .
 Clearly, more work needs to be done to improve prevention, 
treatment and outcome of intracranial haemorrhage  [13] . A sum-
mary statement of a recent NINDS workshop may help to iden-
tify some research goals specific to intracerebral haemorrhage 
 [14] . In addition, and as a supplement to the European ‘stroke re-
search priorities for the next decade’, we offer the following glob-
al research objectives for intracranial haemorrhage.
 • Develop and test diagnostic strategies for the detection of the 
various underlying congenital (arteriovenous malformations), 
genetic (cavernous malformations, familial aneurysms, etc.) 
and acquired (cerebral small-vessel disease, amyloid angiopa-
thy, dural fistulas, etc.) causes of intracranial haemorrhage in 
a multicentre setting. 
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 We were delighted by the recent initiative to define ‘stroke 
research priorities for the next decade’  [1] . The summary state-
ment – reprints of which were kindly included in the congress 
material at last year’s European Stroke Conference in Brussels – 
clearly defines research priorities regarding cerebral reperfusion, 
delivery of stroke care, brain protection, recovery, cerebrovascu-
lar biology and stroke imaging.
 Rather surprisingly, the ‘representative view of the European 
scientific community’ has overlooked intracranial haemorrhage 
altogether. This is somewhat counterintuitive, as intracranial 
haemorrhage (i.e. the various subsets of intracerebral, subarach-
noid, intraventricular and subdural haemorrhage) carries an even 
higher morbidity and case fatality than ischaemic stroke and con-
sequently represents a rising burden of illness within an increas-
ingly aging European population. Despite   180,000 new intracra-
nial haemorrhage cases occurring in the EU every year, no spe-
cific treatment strategies are readily available (with the exception 
of subarachnoid haemorrhage), and no diagnostic standards for 
the detection of the various underlying causes have been estab-
lished so far.
 The aetiology, natural history and treatment options for non-
traumatic intracerebral haemorrhage have attracted increasing 
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 • Establish specific interventions in the management of acute 
intracerebral (blood pressure management, haemostatic ther-
apy, invasive treatment strategies, etc.) and subarachnoid 
haemorrhage (timing and type of intervention for bleeding 
source, prevention and treatment of secondary complications, 
etc.) based on randomized controlled multicentre trials. 
 • Evaluate the risk/benefit ratio of invasive therapy for unrup-
tured vascular pathologies (unruptured aneurysms, unrup-
tured brain arteriovenous malformations, unruptured cav-
ernous malformations, etc.) and the effectiveness of radiolog-
ical follow-up in prospective epidemiological and randomized 
controlled clinical studies. 
 • Evaluate the risk/benefit ratio of invasive therapy for vascular 
pathologies underlying intracranial haemorrhage in the elder-
ly (e.g. 15% of all subarachnoid haemorrhage patients are old-
er than 70 years of age). 
 • Increase awareness of cognitive deficits and psychosocial 
problems after intracranial haemorrhage, develop facilities for 
information (for patients, family and employers) after dis-
charge and help in coping with these problems [e.g. half the 
patients with subarachnoid haemorrhage are younger than 55 
years of age, and only a minority resume their pre-morbid 
(working) activities]. 
 • Optimize multidisciplinary diagnostic and therapeutic strate-
gies for acute intracranial haemorrhage of any cause, includ-
ing vascular neurology, diagnostic and interventional neuro-
radiology, neurosurgery, anaesthesiology and neuropsychol-
ogy, to name but a few. 
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 The participants of the European Stroke Workshop wish to 
thank the authors for their initiative to provide recommendations 
for future research goals in the field of intracerebral hemorrhage 
 [1] . The clinical studies that are outlined by this group of stroke 
researchers are all valuable and deserve our full support.
 It is important to understand that our paper on stroke re-
search priorities  [2] should not be interpreted as an all-encom-
passing statement. The publication rather summarizes the key 
issues that were discussed at the Stroke Workshop in Brussels, 
which was organized by the European Commission. This event 
included a talk by the Director of Health Research, Dr. Octavi 
Quintana Trias, on the goals of the upcoming Seventh Frame-
work Programme. Coordinators of recent stroke-related projects 
funded by the European Union (STROKEGENE, UMEDS, MOL-
STROKE and EUROCLOT) were invited to summarize the high-
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